Mené en Suède sur 2 867 femmes présentant un indice de masse corporelle supérieur ou égal à 38 (âge moyen : 48 ans ; durée médiane de suivi : 23,9 ans), cet essai évalue l'association entre une chirurgie bariatrique et le risque de cancer du sein (154 cas)

Breast Cancer Risk After Bariatric Surgery and Influence of Insulin Levels: A Nonrandomized Controlled Trial

Kristensson, Felipe M. ; Andersson-Assarsson, Johanna C. ; Peltonen, Markku ; Jacobson, Peter ; Ahlin, Sofie ; Svensson, Per-Arne ; Sjöholm, Kajsa ; Carlsson, Lena M. S. ; Taube, Magdalena

Obesity and insulin are risk factors for breast cancer, and retrospective studies suggest bariatric surgery reduces breast cancer risk in women. However, long-term prospective data on breast cancer risk after bariatric surgery and the role of baseline insulin levels are lacking.To examine if bariatric surgery is associated with breast cancer incidence in women and if treatment benefit is modified by baseline insulin levels.The Swedish Obese Subjects (SOS) study was a nonrandomized intervention [...]

Mené en Suède sur 2 867 femmes présentant un indice de masse corporelle supérieur ou égal à 38 (âge moyen : 48 ans ; durée médiane de suivi : 23,9 ans), cet essai évalue l'association entre une chirurgie bariatrique et le risque de cancer du sein (154 cas)

Bariatric Surgery Reduces Breast Cancer Incidence in a Prospective Trial

Kulkarni, Swati A. ; Sterbling, Helene M.

In this issue of JAMA Surgery, Kristensson et al build on their previous research using participants from the Swedish Obese Subjects Study (SOS), a prospective, controlled trial comparing bariatric surgery to usual care. The SOS investigators initially reported a decrease in cancer incidence after bariatric surgery in women, but not in men. Subsequently, in the cohort of women participants, they reported that bariatric surgery reduced the incidence of female-specific cancers, particularly in [...]

Menée à partir des données 2006-2020 utilisées pour mesurer l'efficacité du programme anglais de vaccination contre le papillomavirus humain (HPV), cette étude analyse l'incidence du cancer du col de l'utérus et des néoplasies intraépithéliales cervicales de grade 3 (CIN3) au cours d'une année supplémentaire de suivi et en fonction du statut socio-économique

HPV vaccine: the key to eliminating cervical cancer inequities

Amboree, Trisha L ; Paguio, Joslyn ; Sonawane, Kalyani

The human papillomavirus (HPV) vaccine protects individuals from HPV strains that cause cancer. Evidence of its effectiveness in eliminating invasive cervical cancers is growing.1234 In a linked paper, Falcaro and colleagues (doi:10.1136/bmj-2023-077341) provide further evidence for the impact of HPV vaccination in eliminating invasive cancers.5 They also answered the vexed question of whether national HPV vaccination programmes magnify or narrow cervical cancer inequities. Women from lower [...]

Menée à partir des données 2006-2020 utilisées pour mesurer l'efficacité du programme anglais de vaccination contre le papillomavirus humain (HPV), cette étude analyse l'incidence du cancer du col de l'utérus et des néoplasies intraépithéliales cervicales de grade 3 (CIN3) au cours d'une année supplémentaire de suivi et en fonction du statut socio-économique

Effect of the HPV vaccination programme on incidence of cervical cancer and grade 3 cervical intraepithelial neoplasia by socioeconomic deprivation in England: population based observational study

Falcaro, Milena ; Soldan, Kate ; Ndlela, Busani ; Sasieni, Peter

Objectives: To replicate previous analyses on the effectiveness of the English human papillomavirus (HPV) vaccination programme on incidence of cervical cancer and grade 3 cervical intraepithelial neoplasia (CIN3) using 12 additional months of follow-up, and to investigate effectiveness across levels of socioeconomic deprivation. Design: Observational study. Setting: England, UK. Participants: Women aged 20-64 years resident in England between January 2006 and June 2020 including 29 968 with a [...]

Mené sur 160 adultes utilisateurs d'e-cigarettes à la nicotine mais ne fumant pas de cigarettes (âge moyen : 33,6 ans ; 52 % de femmes), cet essai randomisé multicentrique évalue l'efficacité d'un traitement de 12 semaines par cytisinicline pour arrêter le vapotage

Time for a Focus on Cessation of E-Cigarettes

Krishnan-Sarin, Suchitra ; Fucito, Lisa M.

E-cigarettes, which were introduced in the US market in 2007, have experienced tremendous growth in the US and globally and are the focus of an intense and often controversial public health debate concerning harms and benefits. The most important potential benefit of e-cigarettes is to assist with cigarette smoking cessation and reduce exposure to cigarette-related harm among those who completely switch to e-cigarettes. However, e-cigarettes can also produce harm and serve to initiate and [...]

Mené sur 160 adultes utilisateurs d'e-cigarettes à la nicotine mais ne fumant pas de cigarettes (âge moyen : 33,6 ans ; 52 % de femmes), cet essai randomisé multicentrique évalue l'efficacité d'un traitement de 12 semaines par cytisinicline pour arrêter le vapotage

Cytisinicline for Vaping Cessation in Adults Using Nicotine E-Cigarettes: The ORCA-V1 Randomized Clinical Trial

Rigotti, Nancy A. ; Benowitz, Neal L. ; Prochaska, Judith J. ; Cain, Daniel F. ; Ball, Julie ; Clarke, Anthony ; Blumenstein, Brent A. ; Jacobs, Cindy

The prevalence of e-cigarette use among US adults, especially young adults, is rising. Many would like to quit vaping nicotine but are unable to do so. Cytisinicline, a plant-based alkaloid, targets nicotinic acetylcholine receptors, reduces nicotine dependence, and helps adults to stop smoking cigarettes. Cytisinicline may also help e-cigarette users to quit vaping.To determine the efficacy and safety of cytisinicline vs placebo to produce abstinence from e-cigarette use in adults seeking to [...]